Vol. 10 No. 1 (2023): January-December 2023

Published: 2023-12-31

Full Issue

Point of View

Original Research Articles

  • Time to market access in Italy: duration of the P&R process for rare disease drugs

    Andrea Marcellusi, Paola Raimondo, Carlotta Galeone, Pier Luigi Canonico
    79-88
    DOI: https://doi.org/10.33393/grhta.2023.2610

  • Orphan drugs in Italy: availability and time-to-access at regional level

    Maria Lucia Marino, Eva Alessi, Aurora Di Filippo, Barbara Polistena, Francesco Macchia, Federico Spandonaro, Francesco Trotta
    89-97
    DOI: https://doi.org/10.33393/grhta.2023.2641

  • Unmet need: definitions, literature evidence and implications for HTA

    Claudio Jommi, Michela Meregaglia, Carmine Pinto
    70-78
    DOI: https://doi.org/10.33393/grhta.2023.2624

  • Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy

    Alison Davie, Sory Traoré, Massimo Giovannitti, Giuseppe Pompilio, Mark Lambton, Esra Cakar, Anuja Chatterjee
    62-69
    DOI: https://doi.org/10.33393/grhta.2023.2561

  • Good practices for the development of budget impact models at regional level

    Andrea Marcellusi, Angela Ragonese, Andrea Marinozzi, Alberto Bortolami, Sara Mucherino, Carolina Moreno, Amalia Antenori, Matteo Ferrario, Claudia Simonelli, Matteo Zanuzzi, Marco Cicoira, Ruggero Lasala, Francesco Russoniello, Francesco Attanasio, Caterina Donati, Chiara Roni, Fabrizio Gemmi, Francesco Saverio Mennini, Pierluigi Russo, Giovanna Scroccaro, PierLuigi Canonico
    53-61
    DOI: https://doi.org/10.33393/grhta.2023.2582

  • COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment

    Beatrice Canali, Laura Candelora, Francesca Fiorentino, Tom Halmos, Paola La Malfa, Francesca Massara, Chiara Vassallo, Duccio Urbinati
    46-52
    DOI: https://doi.org/10.33393/grhta.2023.2560

  • Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy

    Francesca Fiorentino, Paolo Di Rienzo
    29-39
    DOI: https://doi.org/10.33393/grhta.2023.2507

  • Cost-effectiveness of IMI/CIL/REL for the treatment of carbapenem non-susceptible Gram-negative bacterial infections

    Martina Paoletti, Andrea Marcellusi, Joe Yang, Francesco Saverio Mennini
    18-28
    DOI: https://doi.org/10.33393/grhta.2023.2488

  • The role of patient-reported outcomes in reimbursement decisions and drug innovation in Italy

    Francesco Malandrini, Cesare Borroni, Michela Meregaglia, Massimiliano Sarra, Oriana Ciani
    12-17
    DOI: https://doi.org/10.33393/grhta.2023.2514

  • Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis

    Ludovica Borsoi, Patrizio Armeni, Maria Luisa Brandi
    1-11
    DOI: https://doi.org/10.33393/grhta.2023.2492